2-(5-甲酰基-呋喃-2-基)-苯甲酸 | 88460-72-4

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 中文名称: 2-(5-甲酰基-呋喃-2-基)-苯甲酸
• 英文名称: 2-(5-formylfuran-2-yl)benzoic acid
• CAS: 88460-72-4
• 化学式: C₁₂H₈O₄
• mdl: MFCD00454839
• 分子量: 216.193
• InChiKey: IOKDFDKKAQANIA-UHFFFAOYSA-N

物化性质

• 沸点：
  408.6±35.0 °C(Predicted)
• 密度：
  1.336±0.06 g/cm3(Predicted)
• 溶解度：
  可溶于DMSO（少许）、甲醇（少许）

计算性质

• 辛醇/水分配系数(LogP)：
  2
• 重原子数：
  16
• 可旋转键数：
  3
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  67.5
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险性防范说明：
  P261,P264,P270,P271,P280,P301+P312,P302+P352,P304+P340,P330,P363,P501
• 危险性描述：
  H302,H312,H332

反应信息

• 作为反应物：
  描述：

  2-(5-甲酰基-呋喃-2-基)-苯甲酸 、 nalidixic acid hydrazide 在 硫酸 作用下， 以 乙醇 为溶剂， 以61%的产率得到N-[{5-(2-carboxyphenyl)-2-furanyl}methylidene]-1-ethyl-1,4-dihydro-7-methyl-4-oxo-1,8-naphthyridine-3-carbohydrazide
  参考文献：
  名称：

  萘啶酸希夫碱：合成与生物学评价

  摘要：

  背景：寄生虫和原生动物感染引起的发病率和死亡率的上升趋势，尤其是在第三世界国家。耐药微生物病原体使情况进一步恶化。 目的：与取代的糠醛和萘啶酸的1,8-萘啶核有关的抗菌和驱虫活性促使我们合成了一些新的喹诺酮席夫碱，目的是获得有效的抗菌和驱虫剂，从而提高安全性和疗效。 方法：在无水条件下，萘啶酸甲酯1与水合肼反应，设计合成了一系列新的基于1,8萘啶的席夫碱。生成1-乙基-1,4-二氢-7-甲基-4-氧代-1，8-萘啶-3-碳酰肼2。将化合物2进一步用几种糠醛处理以提供所需的席夫碱（3a-k）。研究了席夫碱对四种革兰氏阳性和四种革兰氏阴性细菌菌株的体外抗菌活性。还测试了新制备的席夫碱对蠕虫后腐殖质和Perionyx exavatus的驱虫活性。 结果：所制备化合物的化学结构和身份已通过其光谱数据证实。总体而言，席夫碱（3a-k）表现出良好的抗菌活性，有趣的是，五种化合物显示出比标准药物氨苄青霉

  DOI：

  10.2174/1570180814666170710160751
• 作为产物：
  描述：

  糠醛 、 邻氨基苯甲酸 在 盐酸 、 sodium nitrite 、 copper(II) choride dihydrate 作用下， 以 丙酮 为溶剂， 以20%的产率得到2-(5-甲酰基-呋喃-2-基)-苯甲酸
  参考文献：
  名称：

  Identification, synthesis and evaluation of SARS-CoV and MERS-CoV 3C-like protease inhibitors

  摘要：

  Severe acute respiratory syndrome (SARS) led to a life-threatening form of atypical pneumonia in late 2002. Following that, Middle East Respiratory Syndrome (MERS-CoV) has recently emerged, killing about 36% of patients infected globally, mainly in Saudi Arabia and South Korea. Based on a scaffold we reported for inhibiting neuraminidase (NA), we synthesized the analogues and identified compounds with low micromolar inhibitory activity against 3CL(pro) of SARS-CoV and MERS-CoV. Docking studies show that a carboxylate present at either R-1 or R-4 destabilizes the oxyanion hole in the 3CL(pro). Interestingly, 3f, 3g and 3m could inhibit both NA and 3CL(pro) and serve as a starting point to develop broad-spectrum antiviral agents. (C) 2016 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmc.2016.05.013

文献信息

• Common ligand mimics: thiazolidinediones and rhodanines
  申请人：——

  公开号：US20040009526A1

  公开（公告）日：2004-01-15

  The present invention provides common ligand mimics that act as common ligands for a receptor family. The present invention also provides bi-ligands containing these common ligand mimics. Bi-ligands of the invention provide enhanced affinity and/or selectivity of ligand binding to a receptor or receptor family through the synergistic action of the common ligand mimic and specificity ligand which compose the bi-ligand. The present invention also provides combinatorial libraries containing the common ligand mimics and bi-ligands of the invention. Further, the present invention provides methods for manufacturing the common ligand mimics and bi-ligands of the invention and methods for assaying the combinatorial libraries of the invention.

  本发明提供了作为受体家族通用配体的共同配体模拟物。本发明还提供了含有这些共同配体模拟物的双配体。本发明的双配体通过共同配体模拟物和构成双配体的特异性配体的协同作用，提供了对受体或受体家族的配体结合的增强亲和力和/或选择性。本发明还提供了包含共同配体模拟物和本发明的双配体的组合库。此外，本发明提供了制造共同配体模拟物和本发明的双配体的方法，以及检测本发明的组合库的方法。
• RHODANINES AND RELATED HETEROCYCLES AS KINASE INHIBITORS
  申请人：HADDACH Mustapha

  公开号：US20100331315A1

  公开（公告）日：2010-12-30

  The invention provides compounds that inhibit PIM kinases and/or CK2, and compositions containing such compounds. These compounds and compositions are useful for treating proliferative disorders such as cancer, as well as other kinase-associated conditions including inflammation, pain, vascular disorders, pathogenic infections and certain immunological disorders.

  该发明提供了能够抑制PIM激酶和/或CK2的化合物以及含有这些化合物的组合物。这些化合物和组合物可用于治疗增殖性疾病如癌症，以及其他与激酶相关的疾病，包括炎症、疼痛、血管疾病、病原体感染和某些免疫性疾病。
• Bi-functional complexes and methods for making and using such complexes
  申请人：Gouliaev Alex Haahr

  公开号：US11225655B2

  公开（公告）日：2022-01-18

  The present invention is directed to a method for the synthesis of a bi-functional complex comprising a molecule part and an identifier oligonucleotide part identifying the molecule part. A part of the synthesis method according to the present invention is preferably conducted in one or more organic solvents when a nascent bi-functional complex comprising an optionally protected tag or oligonucleotide identifier is linked to a solid support, and another part of the synthesis method is preferably conducted under conditions suitable for enzymatic addition of an oligonucleotide tag to a nascent bi-functional complex in solution.

  本发明涉及一种合成双功能复合物的方法，该复合物包括分子部分和识别分子部分的识别寡核苷酸部分。根据本发明的合成方法的一部分优选在一种或多种有机溶剂中进行，此时包含可选保护标签或寡核苷酸标识符的新生双功能复合物与固体支持物相连接，合成方法的另一部分优选在适合于将寡核苷酸标签酶加到溶液中的新生双功能复合物的条件下进行。
• Furan-2-ylmethylene Thiazolidinediones as Novel, Potent, and Selective Inhibitors of Phosphoinositide 3-Kinase γ
  作者：Vincent Pomel、Jasna Klicic、David Covini、Dennis D. Church、Jeffrey P. Shaw、Karen Roulin、Fabienne Burgat-Charvillon、Delphine Valognes、Montserrat Camps、Christian Chabert、Corinne Gillieron、Bernard Françon、Dominique Perrin、Didier Leroy、Denise Gretener、Anthony Nichols、Pierre Alain Vitte、Susanna Carboni、Christian Rommel、Matthias K. Schwarz、Thomas Rückle

  DOI：10.1021/jm0601598

  日期：2006.6.1

  Class I phosphoinositide 3-kinases (PI3Ks), in particular PI3K gamma, have become attractive drug targets for inflammatory and autoimmune diseases. Here, we disclose a novel series of furan-2-ylmethylene thiazolidinediones as selective, ATP-competitive PI3K gamma inhibitors. Structure-based design and X-ray crystallography of complexes formed by inhibitors bound to PI3K gamma identified key pharmacophore features for potency and selectivity. An acidic NH group on the thiazolidinedione moiety and a hydroxy group on the furan-2-yl-phenyl part of the molecule play crucial roles in binding to PI3K and contribute to class IB PI3K selectivity. Compound 26 (AS-252424), a potent and selective small-molecule PI3K gamma inhibitor emerging from these efforts, was further profiled in three different cellular PI3K assays and shown to be selective for class IB PI3K-mediated cellular effects. Oral administration of 26 in a mouse model of acute peritonitis led to a significant reduction of leukocyte recruitment.
• Identification, Synthesis, and Evaluation of New Neuraminidase Inhibitors
  作者：Vathan Kumar、Chih-Kang Chang、Kian-Pin Tan、Young-Sik Jung、Shih-Hsun Chen、Yih-Shyun E. Cheng、Po-Huang Liang

  DOI：10.1021/ol502410x

  日期：2014.10.3

  High-throughput screening was performed on similar to 6800 compounds to identify KR-72039 as an inhibitor of H1N1 and H5N1 neuraminidases (NAs). Structureactivity relationship studies led to 3e, which inhibited H5N1 NA with an IC50 of 2.8 mu M and blocked viral replication. Docking analysis shows that compounds bind to loop-430 around the NA active site. Compound 3l additionally inhibited H7N9 NA, making it a dual inhibitor of N1- and N2-type NAs.